Human chromosome 8p23 is known as a region that is associated with loss of heterozygosity (LOH), which is frequently deleted in hepatocellular carcinoma (HCC) tissues. We report here the characterization of a gene for a liver-related putative tumor suppressor (LPTS) localized at 8p23, that was isolated by allelic-loss mapping and positional candidate cloning. The expression of the gene for LPTS was ubiquitous in normal human tissues, albeit at relatively low levels, whereas levels appeared to be significantly reduced, or sometimes undetectable in HCC cells and neoplastic tissues. Thus, it appeared that LPTS might be involved in the control of cell proliferation. Indeed, we observed the significant suppression of growth and growth arrest of SMMC-7721 HCC cells after introduction of the gene for LPTS. We also used antisense oligodeoxynucleotides (AS-ODNs) to suppress the expression of LPTS in normal liver cells L02. Several ASODNs specific for LPTS mRNA significantly enhanced cell growth, whereas control oligodeoxynucleotides (ODNs) did not. Our results suggest that LPTS might be a growthinhibitory protein in human hepatocytes. (HEPATOLOGY 2000;32:721-727.)
Human hepatocellular carcinoma (HCC) is one of the most common malignancies of the liver. Similar to other malignancies, HCC manifested the abnormalities of chromosomes such as deletions, duplications, and translocations, but the molecular mechanism responsible for the malignant phenotype has not yet been elucidated. Comparative genomic hybridization revealed that human chromosome 8p23 is one of the loci associated with alterations such as loss and gain. 1, 2 It has been shown that sequential accumulation of genetic alterations in the genome plays a central role in the development of cancer, including the activation of protooncogenes and the inactivation of tumor suppressor genes. 3, 4 Protooncogenes, such as ras, are rarely changed in primary HCC and appear not to be related in any major way to the pathogenesis of HCC. 5 By contrast, chromosome deletions at the sites of tumor suppressor genes have been frequently detected in many cases of HCC, suggesting that the inactivation of tumor suppressor genes might be critical for the development of HCC. However, no relevant tumor suppressor gene has yet been identified in patients with HCC.
Somatic inactivation of a tumor suppressor gene, usually achieved by intragenic mutation in one allele of the gene with subsequent loss of a chromosome region that spans the second allele, showed loss of heterozygosity (LOH). 6 Mapping of the hotspot regions of tumor suppressor genes can be achieved by examining regions with high-frequency LOH. Among the various deleted chromosome regions identified by several laboratories, chromosome 8p has a particularly high frequency of LOH. 1, [6] [7] [8] [9] Approximately 60% of HCC tumors were shown to exhibit LOH at 1 or more loci at 8p with 3 distinct, minimal deleted regions, namely 8p21 (13 centi Morgan [cM]), 8p22 (9 cM), and 8p23 (5 cM). 10 The microsatellite marker D8S277, located at 8p23, is a possible sequencetagged site (STS) landmark for such LOH in cases of HCC. 6 Chromosome 8p has also been shown to be a site of integration of hepatitis B virus (HBV) in HBV-positive cases of HCC. 11 The integration of HBV appears to be a major risk factor in hepatocarcinogenesis, contributing to the development of HCC by disrupting the chromosomal region that includes a tumor suppressor gene(s). Histological analysis has shown that loss of chromosome 8p23 plays a key role in the progression of HCC. 12, 13 We used the strategy known as positional candidate cloning to select the marker D8S277 at 8p23. We identified several expressed sequenced tags (ESTs) close to D8S277. Using these ESTs, we isolated the cDNA for a novel liver-related putative tumor suppressor gene (LPTS) from a cDNA library prepared from human hepatocytes. We then examined the effects of expression of LPTS on the proliferation of normal liver cells (L02) and HCC cells (SMMC-7721). Our results suggest that LPTS, encoded by a gene on chromosome 8p23, might be a growth-inhibitory protein in liver cells.
MATERIALS AND METHODS
Samples of Primary HCC, Adjacent Tissues, and Cell Lines. All samples of primary HCC (Ks), adjacent samples of nontumorous tissues (Ls), and samples of normal liver tissues (Ns) were obtained from Eastern Hepatobiliary Surgery Hospital (Shanghai, P.R. China). The serial numbers of samples were those recorded by the hospital. All tested patients with HCC, with the exception of K20 and K16, were positive for the HBV surface antigen. The samples of normal tissue were from patients with cavernous hemangioma and were negative for the HBV surface antigen. All tissues were placed in liquid nitrogen immediately after surgical resection. The HCC cell lines HepG2, SMMC-7721, and Bel-7402 and the line of normal liver cells L02 were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, P.R. China). HepG2 and Bel-7402 cells were cultured in Dulbecco's Modified Eagle Medium (DMED; Life Technologies Inc., Grand Island, NY) supplemented with 10% fetal calf serum (FCS; Life Technologies Inc.) and L02 and SMMC-7721 cells were cultured in RPMI medium 1640 (Life Technologies Inc.) plus 10% FCS.
Cloning of cDNA for LPTS. We designed primers P1 (5Ј-CT-GAGAGCCACGATTGAGAACATT-3Ј) and P2 (5Ј-CTGCAGAGT-TACGCACGTCCTGATTC-3Ј) by reference to the sequences of EST AA700052 and H22495, which shared with that of unigene Hs.99829. We introduced a PstI site (underlined) at the 5Ј end of P2 to facilitate further cloning. Reverse transcription was performed in a 50-L reaction mixture that contained 1 g of total RNA from normal liver tissue, 1 L of Thermoscript reverse transcriptase (15 units; Life Technologies Inc., Gaithersburg MD) and oligo (dT) 20 as the primer. The polymerase chain reaction (PCR) was performed in a Programmed Thermal Controller (PTC-100, MJ Research Inc., Watertown MA) with 30 cycles at 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 90 seconds with 1 unit of Platinum Taq DNA Polymerase High Fidelity (Life Technologies Inc.). PCR product was cloned into the T-easy vector (Promega Co., Madison WI), and the nucleotide sequence was determined with a fluorescent automated 377 DNA sequencer (Haojia Co. Shanghai, P.R. China). The nucleotide sequence was analyzed with the BLAST program 14 using the GenBank and SwissProt databases.
Extraction of RNA and RNA Blot Hybridization. Total RNA was extracted with TRIZOL reagent (Life Technologies Inc.) in accordance with the manufacturer's protocol. A 20-g aliquot of total RNA was fractionated by electrophoresis on a denaturing agarose gel and then transferred to Hybond-N ϩ nylon membrane (Amersham Pharmacia Biotech, Ltd., Buckinghamshire, UK). 15 Multiple-tissue Northern blot filter with 2 g of poly(A) ϩ RNA each from various human tissues was obtained from CLONTECH Inc. (Palo Alto, CA). The probe for Northern hybridization was a ϳ800-base pair (bp) fragment obtained by digestion with StuI and BamHI of LPTS cDNA that had been radiolabeled with [ 32 P]dCTP by the random primer method, as described in the manufacturers protocol (TaKaRa Inc., DaLian, P.R. China). The blot was incubated first for 30 minutes and then hybridized for one hour at 68°C in ExpressHyb hybridization solution (CLONTECH Inc.). The membrane filter was washed at room temperature for 40 minutes in 2ϫ SSC (1ϫ SSC: 150 mmol/L sodium chloride, 15 mmol/L sodium citrate, pH 7.0) plus 0.05% SDS and then at 50°C for another 40 minutes in 0.1ϫ SSC plus 0.1% SDS. Filters were then exposed to XAR-5 film (Eastman Kodak Co., Rochester MA.) with an intensifying screen.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR). Total RNA was reverse transcribed in a 20-L reaction mixture that contained 1 g of total RNA from normal liver, cancerous liver or adjacent noncancerous liver, or from cultured cell lines, 2.5 pmol of oligo dT-adaptor primer and 1 L of AMV reverse transcriptase XL (5 units, TaKaRa Inc.). The reaction mixture was incubated at 42°C for 30 minutes and then boiled to inactivate the enzyme. The reaction mixture was then divided into 2 parts for detection of the target gene and for PCR with ␤-actin mRNA as the internal control. The primers for detection of the level of the RNA were designated LPTS (P1 and P3, 5Ј-CTGAAGCCCAAAAAGAGGAGAGG-3Ј) and ␤-actin (␤-actin1, 5Ј-TGACGGGGTCACCCACACTGTGCCCATCTA-3Ј; ␤-actin2, 5Ј-CTA-GAAGCATTTGCGGTGGACGATGGAGGG-3Ј), respectively. PCR was performed as follows: 94°C for 2 minutes and then 30 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 40 seconds. The products of PCR were separated by electrophoresis on a 1% agarose gel.
Formation of Stable Colonies of Transformed Cells. HCC cells (SMMC-7721, approximately 2 ϫ 10 5 cells per 60-mm dish) were transfected with 2 g of pcDNA3 (Invitrogen, Inc. Carlsbad CA) that included the full length cDNA for LPTS or pcDNA3, the control vector, with LipofectAMIN reagent (Life Technologies, Inc.) according to the manufacturer's protocol. Then, 24 hours after transfection, G418 (Life Technologies, Inc.) was added to the medium at a final concentration of 700 g/mL. Selection was continued for 3 weeks. Colonies were fixed with methanol and stained with Giemsa for enumeration of transformed foci. Transformed colonies were confirmed by amplification of the neo gene with the primers neo1 (5Ј-CAAGATGGATTGCACG-CAGG-3Ј) and neo2 5Ј-CCCGCTCAGAAGAACTCGTC-3Ј).
Effect of Antisense Oligodeoxynucleotides (AS-ODNs) on Cell Growth.
The method for antisense assay was performed as described by Liu et al. 16, 17 Cells were seeded in 96-well microtiter plates (Corning Inc., Corning, NY) at approximately 1.5 ϫ 10 3 cells in 100 L of medium per well. After cells had adhered to the plate overnight, the medium was replaced with fresh medium that contained 5 mol/L AS-ODNs. The medium was replaced with fresh medium plus AS-ODNs at the same concentration at 2-day intervals. Viable cells were counted by the MTT assay (see later) after 2, 4, and 8 days.
Quantitation of Viable Cells. The MTT colorimetric assay 18 was performed to determine the ability of viable cells to convert a soluble tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT, Sigma Inc., St. Louis, MO) into an insoluble formazan precipitate, corresponding to the number of viable cells. Ten microliters of MTT (5 mg/mL in PBS) solutions were added to each well and also to the control wells without cells. After a 4-hour incubation at 37°C, 80 L of the reaction mixture were removed and then 100 L of dimethyl sulfoxide (DMSO, Sigma Co.) were added to each well. After thorough mixing, the absorbance of the solution in each well was determined with a microplate reader (model 450; BioRad, Hercules, CA) at test and reference wavelengths of 570 nm and 630 nm, respectively.
RESULTS
We selected candidate ESTs for positional cloning by reference to Genemap98' from NCBI (http://www.ncbi.nlm.nih. gov/genemap). 19 Ten ESTs around the marker D8S277 were selected for further analysis. We then identified EST AA700052, which was derived from a cDNA library prepared from human liver cells. EST AA700052 belonged to the unigene cluster Hs.99829. Using available information about Hs.99829, we recovered a 1.3-kb cDNA fragment after RT-PCR with EST primers from normal liver tissue and then subcloned the fragment into the T-easy vector to generated pT-LPTS, which encoded LPTS (liver-related putative tumor suppressor). The cDNA for LPTS consisted of 1,316 nucleotides with an open reading frame that encoded 174 amino acids (Fig. 1) . There was an ATG triplet, starting at nucleotide (nt) 133, that was in an appropriate context for the initiation of translation (Fig. 1) . 20 The putative polypeptide had a predicted molecular mass of 19.1 kd. Searches of the GenBank and SwissProt databases revealed 3 extensively homologous sequences in Caenorhabditis elegans (PID: e214883), Drosophila melanogaster (PID: g7302356), and Saccharomyces cerevisiae (PID: g6594229). The deduced LPTS protein was 45% homologous to a 339 amino acid coding region of C. elegans, 46% homologous to a 726 amino acid coding region of D. melanogaster, and 33% identical to a 271 amino acid coding region of S. cerevisiae (Fig. 2) . In the 3Ј-end untranslated region, we identified polyadenylation signals AATAAA at positions 701 and 1261. The cDNA appeared to represent the expressed gene around the D8S277 landmark at the LOH locus.
We analyzed HCC, normal liver tissue, and HCC cell lines by RT-PCR in an effort to detect the expression of the gene for LPTS using primers that corresponded to the 3Ј-end of the untranslated region of the gene. As shown in Fig. 3A and B, we detected variable levels of expression of the gene in HCC samples. An amplified fragment of 328 bp DNA was detected Hybridization was performed with a ϳ800-bp DNA fragment of LPTS cDNA that had been digested with StuI and BamHI as probe. As a loading control, the intensities of the rRNA signals were used. "K" refers to cancerous liver tissue, "L" refers to corresponding adjacent noncancerous tissue, and "N" refers to normal liver tissue. The size of each mRNA was determined by reference to RNA marker. HEPATOLOGY Vol. 32, No. 4, 2000 in the analysis of 6 samples of normal liver tissue (N1, N3, N4, N5, N14, and N15), in a cDNA library prepared from normal liver (Life Technologies, Inc.) and in 1 normal hepatocyte (L02). Among 8 samples of HCC, K26, K53, K54, and K57 yielded a band that corresponded to the amplified 328-bp DNA, whereas no similar band of amplified DNA was generated from the samples of K14, K16, K20, and K59. We also examined the expression of the gene for LPTS in 4 pairs of HCC samples and the corresponding adjacent noncancerous tissue by Northern blotting (Fig. 3C) . The results clearly showed the lower level of expression of the gene for LPTS in three (K91, K96, and K11) of the 4 samples of HCC, as compared with the respective adjacent tissues. We also examined the expression of LPTS gene in 3 lines of HCC cells, namely SMMC-7721, Bel-7402, and HepG2. The gene for LPTS was expressed only in HepG2 cells (Fig. 3A) . Taken together, these results indicate that LPTS is generally not expressed in HCC cells.
We examined the expression of the gene for LPTS in normal human tissues, including heart, brain, placenta, lung, liver, skeletal muscle, and kidney. Transcripts of the gene were clearly identified in all tissues examined, albeit at different levels (Fig. 4) . The transcript was expressed at a relatively high level in skeletal muscle and to a lesser extent in placenta, brain, and lung. In liver, LPTS was expressed at a moderate level. In every case, we detected a single transcript of approximately 1.4 kb.
To examine whether or not LPTS might affect the growth of normal hepatocytes L02, we used antisense technology, adding antisense oligonucleotides (AS-ODNs) directly to the culture medium of L02 cells in an attempt to reduce the expression of LPTS. L02 cells were derived from a human liver and appeared typical normal liver cells being different from HCC cells. Ultra-structural study showed that most of L02 cells appeared to have round nuclei and moderate amount of endoplasmic reticulum, mitochondria, i.e., with characteristics that were still similar to those of human normal liver cells in vivo. 21 L02 cells did not exhibit the features of cancerous cells, but did show the contact inhibition and no colonies formation in soft agar. We selected possible target sequences for ASODNs that were specific to LPTS mRNA (AS1 through AS5) using the PAS program ( Fig. 5A and B) . 22 To examine the effects of nonspecific suppression by AS-ODNs, we used a random 24-mer ODN with a similar GC content to the specific AS-ODNs, as well as 2 sense ODNs (S2 and S3), as controls. As shown in Fig. 5C , 3 AS-ODNs specific for LPTS mRNA, namely AS2, AS3, and AS4, stimulated cell proliferation to a significant extent. The number of L02 cells after treatment with AS-ODNs specific for LPTS mRNA was 2.0-to 2.4-fold greater after 8 days than that of L02 cells without treatment with AS-ODNs. The AS-ODNs against other target sequences in LPTS mRNA, the random ODN and the 2 sense ODNs (S2, S3) had no effect. Thus, the AS-ODNs specific for target sites in LPTS mRNA stimulated cell proliferation in a gene-specific manner.
We next examined whether LPTS could repress the proliferation of the HCC cell line SMMC-7721, which is a wellcharacterized line of HCC cells but was found not to express endogenous LPTS, by introducing the gene encoded for LPTS. We used colony formation assay with selective pressure from G418 for 3 weeks and found a consistent reduction of approximately 70% in colony number when cells had been transfected with the LPTS-expression vector as compared with the control vector ( Fig. 6A and B) . This effect was reproducible and was observed in more than 3 independent transfection experiments. We used PCR to amplify the neo gene from these colonies and showed that they were indeed neomycin resistant colonies (Fig. 6C) . Thus, suppression of clonal outgrowth was clearly the result of the transfection of the LPTSexpression vector. We pooled colonies and examined the expression of the LPTS transcript by Northern blotting. The level of the LPTS transcript was still very low, but a little higher than that in cells transfected with the control pcDNA3 (data not shown). These results indicated that the gene for LPTS could suppress the proliferation of HCC cells.
DISCUSSION
We successfully cloned the cDNA for a novel human HCCrelated gene, the gene for LPTS, by positional candidate cloning 23 using mRNAs derived from normal human liver tissue as template and mapping information in GenBank Genmap98. The cDNA for LPTS included a complete open reading frame from nt 133 to 657 and encoded a protein of 174 amino acids. The length of the cDNA fragment was consistent with the length of the mRNA for LPTS.
The gene for LPTS mapped to chromosome 8p23, a locus with high-frequency LOH (about 42%), near the microsatellite marker D8S277. Molecular analysis of HCC has suggested that there is more than 1 tumor suppressor gene on chromosome 8p23. The gene for LPTS, located at 8p23, was deleted in more than 50% of patients with HCC that we analyzed, and such a frequency is similar to the frequency of LOH (42%). A growing body of evidence suggests that chromosome 8p is active in many types of carcinogenesis and metastasis and that more than 1 tumor suppressor gene is located at 8p. Studies of LOH and comparative genomic hybridization have revealed that these genes are inactivated not only in HCC, but also in a large variety of human malignancies, such as breast, colorectal, prostate, lung, head and neck, pancreatic, and urinary bladder carcinomas. 9, [24] [25] [26] [27] [28] [29] [30] [31] [32] The frequencies of deletion of chromosome 8p are sometimes even higher than those of chromosomes 17p and 13q, which harbor the tumor suppressor genes p53 and Rb, respectively. It was reported that microcell-mediated transfer of chromosome 8 suppressed tumorigenesis or the proliferation of colorectal, breast, and colon cancer cells. [32] [33] [34] [35] Thus, chromosome 8p seems likely to include several tumor suppressor genes with different roles in human malignancies. To date, however, there have been no reports of the identification of a tumor suppressor gene on 8p. The gene for LPTS appears to be a strong candidate for a tumor suppressor gene. It is located in a high-frequency LOH region of chromosome 8p23. In normal human tissues, we detected the expression of the LPTS transcript at different levels. By contrast, more than 50% of samples of HCC did not express the gene for LPTS, whereas samples of normal liver adjacent to HCC did generate evidence for expression of the gene (Fig. 3) . Thus, expression of the gene for LPTS was detected in normal tissues (Fig. 4) , but was frequently undetectable in HCC. Such patterns of expression are typical of tumor suppressor genes. We are now performing the experiments to identify the mutation sites of the gene for LPTS.
To explore the possible roles of LPTS in the control of cell proliferation, we used AS-ODNs in an attempt to suppress its expression. The proliferation of L02 hepatocytes by AS-ODNs specific for the LPTS transcript was significantly enhanced as compared with that of control L02 cells (Fig. 5C ). To determine whether ectopic expression of LPTS could modulate the proliferation of HCC cells, we introduced LPTS cDNA into SMMC-7721 cells. As a result, we detected a significant reduction in the number of colonies and inhibition of proliferation. The level of expression of the gene for LPTS in the colonies after complete selection was low. These experiments indicated that the gene for LPTS could suppress the growth of HCC cells. The stimulatory effects of specific AS-ODNs on L02 cells and the suppressive effect of the LPTS cDNA on HCC cells showed that the gene for LPTS is a growth-arrest gene that acts directly or indirectly to control the proliferation of cells. The expression of tumor suppressor genes is usually down-regulated in cancerous tissue and significant in the normal tissues. The products of such genes regulate cell growth and differentiation in a negative fashion and, thus, suppress neoplastic development. 36 It is possible that the total inactivation of the gene for LPTS as a result of deletions or mutations might result in uncontrollable cell growth, possibly leading to the development of a tumor. The tumor-suppressive function of the gene for LPTS and its role in apoptosis require further investigation.
